August 2013 in “Nature Reviews Drug Discovery” New treatments for cancer and skin disorders show promise in disrupting harmful cell interactions and promoting hair growth.
1 citations
,
December 2024 in “Journal of Orthopaedic Research®” Aromoline and DRD4 are potential targets for osteoarthritis treatment.
10 citations
,
August 1998 in “Journal of Investigative Dermatology”
47 citations
,
November 1982 in “Journal of Cardiovascular Pharmacology” Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.
December 2010 in “TSpace” Activating androgen receptors in muscle can increase muscle mass and reduce fat.
69 citations
,
October 2014 in “Stem Cells” PDGF-D boosts stem cell growth and movement, enhancing hair regeneration.
18 citations
,
January 2002 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” New pregnane derivatives were more effective than finasteride at inhibiting a key enzyme for male pattern baldness.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
15 citations
,
May 2009 in “Steroids” Certain compounds reduced hamster flank organ size by inhibiting 5α-reductase, like finasteride, without affecting androgen receptors.
26 citations
,
September 2018 in “Neurobiology of Disease” Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
February 2026 in “Advanced Science” Targeting the p300/AR axis may help treat polycystic ovary syndrome.
41 citations
,
February 2012 in “Journal of Neuroendocrinology” Allopregnanolone helps control oxytocin levels during pregnancy to prevent preterm labor.
April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.
24 citations
,
May 2022 in “Frontiers in Endocrinology” Activating brown fat may help manage PCOS symptoms.
44 citations
,
May 1998 in “PubMed” The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.
3 citations
,
October 2024 in “Frontiers in Pharmacology” Compounds from Pterocarpus indicus may help treat benign prostatic hyperplasia by stopping cell growth.
54 citations
,
May 2015 in “Endocrinology” Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
April 2023 in “Journal of The American Academy of Dermatology” Some drugs linked to growth hormones may increase the chance of hair loss in women.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
103 citations
,
April 2005 in “Experimental dermatology” Prostaglandin F2alpha and related compounds can increase hair growth and darken hair in mice.
March 1998 in “Journal of dermatological science” Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.
123 citations
,
May 2009 in “Journal of Neuroscience” In late pregnancy, allopregnanolone reduces stress responses in rats by affecting brain chemicals.
1 citations
,
October 2022 in “International journal of endocrinology” Dihydrotestosterone changes some hormone-related gene expressions in rat pituitary glands but doesn't affect the estrous cycle.
24 citations
,
April 2013 in “PLOS ONE” TNFα, IFNγ, and Substance P significantly affect prolactin levels in human skin, suggesting new treatments for skin and hair conditions.
14 citations
,
March 2017 in “Brain research” Progesterone and its byproducts control a specific receptor in the brain independently of progesterone receptors, affecting conditions related to the menstrual cycle.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
43 citations
,
August 2010 in “Expert Opinion on Investigational Drugs” Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
54 citations
,
December 2007 in “Best Practice & Research Clinical Endocrinology & Metabolism” Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.